Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity

Clinical Endocrinology

Volumn 83, Issue 1, 2015, Pages 50-58

  Cassar, Samantha ^a,b   Teede, Helena J ^b,c   Harrison, Cheryce L ^b   Joham, Anju E ^b,c   Moran, Lisa J ^b,d   Stepto, Nigel K ^a,b  

^a VICTORIA UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c SOUTHERN HEALTH   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; RETN PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CLINICAL EVALUATION; COMMUNITY CARE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE INFUSION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID METABOLISM; MAJOR CLINICAL STUDY; OBESITY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; CASE CONTROL STUDY; COMPLICATION; GLUCOSE CLAMP TECHNIQUE; METABOLISM; PREDICTIVE VALUE; YOUNG ADULT;

ADULT; BIOMARKERS; C-PEPTIDE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN RESISTANCE; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OVERWEIGHT; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; RESISTIN; YOUNG ADULT;

EID: 84932139689     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12619     Document Type: Article

References (42)

1. March, W.A., Moore, V.M., Willson, K.J., et al,. (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction, 25, 544-551.
2. Moran, L.J., Misso, M.L., Wild, R.A., et al,. (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 16, 347-363.
3. Teede, H., Deeks, A., &, Moran, L., (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine 8, 41. doi: 10.1186/1741-7015-8-41.
4. Stepto, N.K., Cassar, S., Joham, A.E., et al,. (2013) Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction, 28, 777-784.
5. Hudecova, M., Jan, H., Christian, B., et al,. (2012) Long-term reproductive and metabolic consequences of PCOS. Current Diabetes Reviews 8, 444-451.
6. Meyer, C., McGrath, B.P., &, Teede, H.J., (2005) Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. The Journal of Clinical Endocrinology and Metabolism, 90, 5711-5716.
7. Moran, L.J., Strauss, B.J., &, Teede, H.J., (2011) Diabetes risk score in the diagnostic categories of polycystic ovary syndrome. Fertility and Sterility, 95, 1742-1748.
8. Teede, H.J., Misso, M.L., Deeks, A.A., et al,. (2011) Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Medical Journal of Australia, 195, S69-S111.
9. Teede, H.J., Hutchison, S.K., &, Zoungas, S., (2007) The management of insulin resistance in polycystic ovary syndrome. Trends in Endocrinology and Metabolism, 18, 273-279.
10. Dunaif, A., (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews, 18, 774-800.
11. Dunaif, A., Wu, X., Lee, A., et al,. (2001) Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). American Journal of Physiology-Endocrinology and Metabolism, 281, E392-E399.
12. Syed Ikmal, S.I., Zaman Huri, H., Vethakkan, S.R., et al,. (2013) Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease. International Journal of Endocrinology 2013, 698567.
13. Wellen, K.E., &, Hotamisligil, G.S., (2005) Inflammation, stress, and diabetes. The Journal of Clinical Investigation, 115, 1111-1119.
14. Tilg, H., &, Moschen, A.R., (2008) Inflammatory mechanisms in the regulation of insulin resistance. Molecular Medicine, 14, 222-231.
15. Wildman, R.P., Kaplan, R., Manson, J.E., et al,. (2011) Body size phenotypes and inflammation in the Women's Health Initiative Observational Study. Obesity (Silver Spring), 19, 1482-1491.
16. Gnacinska, M., Malgorzewicz, S., Stojek, M., et al,. (2009) Role of adipokines in complications related to obesity. A review. Advances in Medical Sciences, 54, 150-157.
17. Chaput, J.-P., &, Tremblay, A., (2006) Current and novel approaches to the drug therapy of obesity. European Journal of Clinical Pharmacology, 62, 793-803.
18. de Luca, C., &, Olefsky, J.M., (2008) Inflammation and insulin resistance. FEBS Letters, 582, 97-105.
19. Shoelson, S.E., Herrero, L., &, Naaz, A., (2007) Obesity, inflammation, and insulin resistance. Gastroenterology, 132, 2169-2180.
20. Wang, P., Mariman, E., Renes, J., et al,. (2008) The secretory function of adipocytes in the physiology of white adipose tissue. Journal of Cellular Physiology, 216, 3-13.
21. Hutchison, S.K., Stepto, N.K., Harrison, C.L., et al,. (2011) Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 96, E48-E56.
22. Moran, L.J., Cameron, J.D., Strauss, B.J., et al,. (2011) Vascular function in the diagnostic categories of polycystic ovary syndrome. Human Reproduction, 26, 2192-2199.
23. Zou, K.H., O'Malley, A.J., &, Mauri, L., (2007) Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation, 115, 654-657.
24. Grundy, S.M., Brewer, H.B. Jr, Cleeman, J.I., et al,. (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109, 433-438.
25. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M., et al,. (2000) Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Human Reproduction, 15, 1266-1274.
26. Koiou, E., Tziomalos, K., Dinas, K., et al,. (2012) Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome. Endocrine Journal, 59, 21-29.
27. Dunaif, A., Segal, K.R., Futterweit, W., et al,. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 38, 1165-1174.
28. Antuna-Puente, B., Feve, B., Fellahi, S., et al,. (2008) Adipokines: the missing link between insulin resistance and obesity. Diabetes & Metabolism, 34, 2-11.
29. Diamanti-Kandarakis, E., &, Papavassiliou, A.G., (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends in Molecular Medicine, 12, 324-332.
30. Moran, L.J., Hutchison, S.K., Meyer, C., et al,. (2009) A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clinical Science, 116, 761-770.
31. Tarkun, I., Canturk, Z., Arslan, B.C., et al,. (2004) The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocrine Journal, 51, 467-472.
32. Atiomo, W.U., Fox, R., Condon, J.E., et al,. (2000) Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clinical Endocrinology, 52, 487-492.
33. Alessi, M.C., &, Juhan-Vague, I., (2006) PAI-1 and the metabolic syndrome: links, causes, and consequences. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2200-2207.
34. Paradisi, G., Steinberg, H.O., Hempfling, A., et al,. (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation, 103, 1410-1415.
35. Margetic, S., Gazzola, C., Pegg, G.G., et al,. (2002) Leptin: a review of its peripheral actions and interactions. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity, 26, 1407-1433.
36. Wren, A.M., Seal, L.J., Cohen, M.A., et al,. (2001) Ghrelin enhances appetite and increases food intake in humans. The Journal of Clinical Endocrinology and Metabolism, 86, 5992-5995.
37. Chen, X., Jia, X., Qiao, J., et al,. (2013) Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. Journal of Molecular Endocrinology, 50, R21-R37.
38. Repaci, A., Gambineri, A., Pagotto, U., et al,. (2011) Ghrelin and reproductive disorders. Molecular and Cellular Endocrinology, 340, 70-79.
39. Mantzoros, C.S., Dunaif, A., &, Flier, J.S., (1997) Leptin concentrations in the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism, 82, 1687-1691.
40. Murata, M., Okimura, Y., Iida, K., et al,. (2002) Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. The Journal of Biological Chemistry, 277, 5667-5674.
41. Li, W.G., Gavrila, D., Liu, X.B., et al,. (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappa B activation in human endothelial cells. Circulation, 109, 2221-2226.
42. Houjeghani, S., Gargari, B.P., &, Farzadi, L., (2012) Serum leptin and ghrelin levels in women with polycystic ovary syndrome: correlation with anthropometric, metabolic, and endocrine parameters. International Journal of Fertility & Sterility, 6, 117-126.